{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:04Z","timestamp":1786982764847,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40265-021-01522-0","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T06:03:20Z","timestamp":1620367400000},"page":"963-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Melphalan Flufenamide (Melflufen): First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"1","key":"1522_CR1","first-page":"12","volume":"16","author":"PG Richardson","year":"2020","unstructured":"Richardson PG. Melflufen-a novel agent in the treatment of relapsed\/refractory multiple myeloma. US Oncol Hematol Rev. 2020;16(1):12\u20134.","journal-title":"US Oncol Hematol Rev."},{"issue":"10","key":"1522_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9103120","volume":"9","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Blad\u00e9 J, Bringhen S, et al. Melflufen: a peptide-drug conjugate for the treatment of multiple myeloma. J Clin Med. 2020;9(10):1\u201316.","journal-title":"J Clin Med."},{"issue":"4","key":"1522_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00726-013-1648-0","volume":"46","author":"SM Hitzerd","year":"2014","unstructured":"Hitzerd SM, Verbrugge SE, Ossenkoppele G, et al. Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids. 2014;46(4):793\u2013808.","journal-title":"Amino Acids"},{"issue":"17","key":"1522_CR4","first-page":"6307","volume":"9","author":"DM Nanus","year":"2003","unstructured":"Nanus DM. Of peptides and peptidases: the role of cell surface peptidases in cancer. Clin Cancer Res. 2003;9(17):6307\u20139.","journal-title":"Clin Cancer Res."},{"issue":"377","key":"1522_CR5","first-page":"1","volume":"9","author":"F Lehmann","year":"2021","unstructured":"Lehmann F, Wennerberg J. Evolution of nitrogen-based alkylating anticancer agents. Processes. 2021;9(377):1\u201310.","journal-title":"Processes."},{"issue":"39","key":"1522_CR6","doi-asserted-by":"publisher","first-page":"66641","DOI":"10.18632\/oncotarget.18420","volume":"8","author":"M Wickstr\u00f6m","year":"2017","unstructured":"Wickstr\u00f6m M, Nygren P, Larsson R, et al. Melflufen: a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017;8(39):66641\u201355.","journal-title":"Oncotarget"},{"key":"1522_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071527","author":"JJ Miettinen","year":"2021","unstructured":"Miettinen JJ, Kumari R, Traustadottir GA, et al. Aminopeptidase expression in multiple myeloma associates with disease progression and sensitivity to melflufen. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13071527.","journal-title":"Cancers (Basel)."},{"key":"1522_CR8","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma [media release]. 26 Feb 2021. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple-myeloma."},{"key":"1522_CR9","unstructured":"Oncopeptides AB. PEPAXTO\u00ae (melphalan flufenamide): US prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214383s000lbl.pdf. Accessed 18 Mar 2021."},{"issue":"6","key":"1522_CR10","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1007\/s10637-015-0299-2","volume":"33","author":"\u00c5 Berglund","year":"2015","unstructured":"Berglund \u00c5, Ull\u00e9n A, Lisyanskaya A, et al. First-in-human, phase I\/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. Invest New Drugs. 2015;33(6):1232\u201341.","journal-title":"Invest New Drugs."},{"issue":"6","key":"1522_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/10611860310001647140","volume":"11","author":"J Gullbo","year":"2003","unstructured":"Gullbo J, Wickstr\u00f6m M, Tullberg M, et al. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target. 2003;11(6):355\u201363.","journal-title":"J Drug Target."},{"issue":"9","key":"1522_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.bcp.2009.12.022","volume":"79","author":"M Wickstrom","year":"2010","unstructured":"Wickstrom M, Viktorsson K, Lundholm L, et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79(9):1281\u201390.","journal-title":"Biochem Pharmacol."},{"issue":"11","key":"1522_CR13","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","volume":"19","author":"D Chauhan","year":"2013","unstructured":"Chauhan D, Ray A, Viktorsson K, et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013;19(11):3019\u201331.","journal-title":"Clin Cancer Res."},{"key":"1522_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12885-016-2299-9","volume":"16","author":"M Delforoush","year":"2016","unstructured":"Delforoush M, Strese S, Wickstr\u00f6m M, et al. In vitro and in vivo activity of melflufen (J1)in lymphoma. BMC Cancer. 2016;16:263.","journal-title":"BMC Cancer"},{"issue":"4","key":"1522_CR15","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.18632\/oncotarget.13856","volume":"8","author":"S Strese","year":"2017","unstructured":"Strese S, Hassan SB, Velander E, et al. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia. Oncotarget. 2017;8(4):6341\u201352.","journal-title":"Oncotarget"},{"issue":"16 Suppl","key":"1522_CR16","first-page":"2","volume":"80","author":"A Slipicevic","year":"2020","unstructured":"Slipicevic A, Munawar U, Stuhmer T, et al. Melflufen efficacy in multiple myeloma with TP53 aberrations. Cancer Res. 2020;80(16 Suppl):2.","journal-title":"Cancer Res."},{"issue":"Suppl 1","key":"1522_CR17","first-page":"6","volume":"134","author":"K Flanagan","year":"2019","unstructured":"Flanagan K, Majumder MM, Kumari R, et al. In vitro and invivo activity of melflufen in amyloidosis. Blood. 2019;134(Suppl 1):6.","journal-title":"Blood"},{"issue":"18","key":"1522_CR18","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.1002\/cam4.3300","volume":"9","author":"A Schepsky","year":"2020","unstructured":"Schepsky A, Traustadottir GA, Joelsson JP, et al. Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines. Cancer Med. 2020;9(18):6726\u201338.","journal-title":"Cancer Med."},{"issue":"Suppl 1","key":"1522_CR19","first-page":"412","volume":"4","author":"K Byrgazov","year":"2020","unstructured":"Byrgazov K, Besse L, Kraus M, et al. Melflufen is a highly effective antineoplastic agent in bortezomib-resistant multiple myeloma models [abstract no. EP915]. HemaSphere. 2020;4(Suppl 1):412\u20133.","journal-title":"HemaSphere."},{"issue":"7","key":"1522_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Oriol A, Larocca A, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39(7):757\u201367.","journal-title":"J Clin Oncol."},{"issue":"5","key":"1522_CR21","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","volume":"7","author":"PG Richardson","year":"2020","unstructured":"Richardson PG, Bringhen S, Voorhees P, et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1\u20132 study. Lancet Haematol. 2020;7(5):e395\u2013407.","journal-title":"Lancet Haematol."},{"key":"1522_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17302","author":"S Bringhen","year":"2021","unstructured":"Bringhen S, Voorhees PM, Plesner T, et al. Melflufen plus dexamethasone in relapsed\/refractory multiple myeloma: long-term survival follow-up from the phase II study O-12-M1. Br J Haematol. 2021. https:\/\/doi.org\/10.1111\/bjh.17302.","journal-title":"Br J Haematol."},{"issue":"Suppl 1","key":"1522_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2020-135991","volume":"136","author":"EM Ocio","year":"2020","unstructured":"Ocio EM, Efebera YA, Hajek R, et al. ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and daratumumab (dara) or bortezomib (BTZ) in relapsed\/refractory multiple myeloma (RRMM) refractory to an IMiD and\/or a proteasome inhibitor (PI): updated efficacy and safety [abstract no. 417]. Blood. 2020;136(Suppl 1):9\u201310.","journal-title":"Blood"},{"issue":"11","key":"1522_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2217\/fon-2020-0024","volume":"16","author":"F Schjesvold","year":"2020","unstructured":"Schjesvold F, Robak P, Pour L, et al. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. Future Oncol. 2020;16(11):631\u201341.","journal-title":"Future Oncol."},{"issue":"Suppl 1","key":"1522_CR25","first-page":"916","volume":"4","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Ocio EM, Sonneveld P, et al. Lighthouse (OP-108): a phase 3 study of melflufen in combination with daratumumab versus daratumumab in patients with relapsed\/refractory multiple myeloma [abstract no. PB2018]. HemaSphere. 2020;4(Suppl 1):916.","journal-title":"HemaSphere."},{"issue":"Suppl 1","key":"1522_CR26","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood-2019-124244","volume":"134","author":"G Palladini","year":"2019","unstructured":"Palladini G, Schonland SO, Lentzsch S, et al. OP201: A phase 1\/2 study of melflufen and dexamethasone in patients with immunoglobulin light chain (AL) amyloidosis. Blood. 2019;134(Suppl 1):3163.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01522-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01522-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01522-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T11:24:04Z","timestamp":1621855444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01522-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01522-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"7 May 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}